Feature | December 26, 2013

IMV Market Report Shows Nuclear Medicine Providers are Consolidating as Procedure Volume Slows

nuclear imaging spect spect/ct IMV
December 26, 2013 — A report released by IMV Medical Information Division found that providers of nuclear medicine (NM) services are consolidating as procedure volume dropped in the subspecialty from 2008 to 2012. 
 
An estimated 14.5 million nuclear medicine patient studies were performed on 14,825 single-photon emission computed tomography (SPECT) or SPECT/CT in the United States in 2012. Compared with the 16 million patient studies performed in 2008, total nuclear medicine patient studies have decreased about 9 percent, for an average annual decline of 2.5 percent per year from 2008 to 2012. 
 
“We attribute this decline in NM patient studies to several factors, including the impact of precertification requirements from health insurance companies, reduced reimbursement and studies shifting to competing technologies, such as bone studies shifting to PET,” said Lorna Young, senior director of market research, IMV. 
 
IMV’s study also shows that physician practice locations (primarily cardiology practices) are feeling financial pressure due to reduced reimbursement from Medicare and third-party payors. When asked about the issues affecting their future outlook, both hospitals and non-hospitals responded that “reductions in Medicare and third-party reimbursements are causing NM revenue to decline” is their top-rated issue, but managers of physician practices are more likely to rate this as a top issue than are administrators of hospital nuclear medicine departments. 
 
Due to these pressures, the number of physician practices performing nuclear medicine studies has declined 6 percent over the past two years, and this decline is likely to continue. 
 
Respondents from physician office locations were asked if they were planning to pursue certain strategic actions over the next few years, including changing their practice ownership structure to include a joint venture with hospitals. Almost one-third of the respondents are either considering or planning such a change in their practice model. 
 
This in turn is impacting their purchase plans for nuclear medicine cameras. While 29 percent of the nuclear imaging sites in the survey are independent physician office locations, less than 10 percent of the sites planning camera purchases through 2015 will be physician offices. 
 
According to the report, while the nuclear medicine market is currently slowing down with the decline in patient studies and a reduction in the number of sites performing NM studies, there is a relatively large installed base of aging equipment. Of the sites that are planning to purchase NM cameras, almost 90 percent of the planned purchases will be for replacement units.
 
Based on market scenarios for unit sales from 2013 to 2017 provided in the report, IMV anticipates that the years 2015-2017 will be relatively active years for system replacements. One driver for replacement activity is the SPECT/CT camera, which will comprise at least 40 percent of the planned purchases for nuclear medicine cameras.
 
IMV’s 2013 Nuclear Medicine Market Outlook Report describes trends in nuclear medicine patient volume by study type, radiopharmaceutical and pharmacological stress agent utilization, SPECT versus SPECT/CT camera installed base and purchase plans, site operations characteristics and department managers' opinions about the factors affecting the future outlook for nuclear medicine.
 
In the report, IMV also provided market scenarios for nuclear medicine camera purchases from 2013 through 2017. Vendors covered in this report include Cardinal Health, Digirad, GE, Philips, Siemens, Spectrum Dynamics and Triad. 
 
Additional highlights include:
  • A larger 80 percent proportion of the NM studies conducted in nonhospital locations are cardiovascular studies, compared with 46 percent of those conducted in hospitals. Hospitals are more likely to be conducting other procedure types, including bone scans, liver/hepatobiliary, renal, respiratory, infection/abscess and tumor localization studies. 
  • An estimated 8 million myocardial ischemia perfusion studies were performed in 2012, of which 58 percent used pharmacological stress agents, either alone or with exercise. 
  • Just over 25 percent of sites indicated providing neurology applications, and this may grow to more than one-third by 2016.
 
IMV's 2013 Nuclear Medicine Market Outlook Report is based on the responses to an IMV-hosted online survey from 410 nuclear medicine department/facility managers nationwide. Responses were projected to the universe of 6,985 short-term general hospitals, imaging centers and physician practices in the United States that have fixed nuclear medicine cameras as identified by IMV. 
 
For more information: www.imvinfo.com

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.